FDA & Clinical Trials
What Is Accelerated Approval? The FDA Pathway That Gets Drugs to Patients Faster
Accelerated Approval is one of the FDA’s most powerful and most debated regulatory tools. It allows drugs to be approved and reach patients before the company has generated the full clinical evidence that would normally be required — based on the premise that for serious conditions with unmet needs, earlier access to a promising therapy…
What Is Orphan Drug Designation? The FDA Program That Transformed Rare Disease Drug Development
For investors in clinical-stage biotech companies, few regulatory announcements are as consistently positive as an Orphan Drug Designation from the FDA. The designation signals that a drug targets a rare disease — a condition affecting fewer than 200,000 Americans — and that the company developing it is eligible for a suite of financial incentives and…
What Is a Complete Response Letter (CRL)? The FDA’s Most Feared Document Explained
The three letters that biotech investors most dread seeing on a PDUFA date are CRL. A Complete Response Letter from the FDA means the agency has reviewed the drug application and determined it cannot be approved as submitted. Stocks routinely fall 40%, 60%, or more on the day a CRL is announced. But a CRL…
What Are Clinical Trial Phases? Phase 1, 2, and 3 Explained for Investors
When a biotech company announces results from a Phase 2 trial or says it is initiating a Phase 3 study, that language carries specific and important meaning. Clinical trial phases are a defined regulatory framework — not marketing language — and each phase represents a distinct step in the process of proving a drug is…
What Is Breakthrough Therapy Designation? FDA’s Accelerated Path Explained
When the FDA grants a biotech company Breakthrough Therapy Designation for a drug, the market typically reacts immediately — and often positively. The designation is a signal from one of the world’s most respected regulatory agencies that a drug shows early evidence of substantial improvement over existing therapies for a serious condition. For investors in…
What Is a PDUFA Date? The FDA Milestone Every Biotech Investor Should Know
The PDUFA date is one of the most closely watched events on any biotech investor’s calendar. When the FDA sets one for a drug under review, it marks the day the agency has committed to issuing a decision — and the entire market pays attention. A stock can move 30%, 50%, or more in a…
